We at TIEFEENBACHER PHARMACEUTICALS are driven by enabling people around the world a better access to more affordable high-quality medicines. That´s why we are happy to share that we have successfully prepared the launch of the generic version of Apixaban for an early market entry in Canada.
Apixaban is an oral anticoagulant (blood thinner) indicated for the prevention of venous thromboembolism (VTE) in adult patients who have undergone elective hip or knee replacement surgery, for the prevention of stroke and systemic embolism in patients with atrial fibrillation, and for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of their recurrence. The 2,5 mg and 5 mg tablets have been developed in TIEFENBACHER GROUP´s own laboratories in India and will be marketed in Canada by our cooperation partner, one of the biggest generic pharmaceutical companies in the world.
A launch in further international markets will follow. With this early market entry TIEFENBACHER PHARMACEUTICALS achieves nameable savings for the international health care systems and enables millions of patients a better affordable access to a life-improving treatment.
For further information about our pharmaceuticals or medical devices please contact TIEFENBACHER PHARMACEUTICALS: info@aet.eu
TIEFENBACHER PHARMACEUTICALS is as a part of TIEFENBACHER GROUP – pioneering healthcare since 1963. Please visit us on: www.aet.eu and www.tiefenbachergroup.com
